MGI Pharma reports Phase II data

Results of MOGN's Phase II trial of irofulven hydroxymethylacylfulvene to treat advanced pancreatic cancer patients who had failed treatment with Eli Lilly's Gemzar gemcitabine showed that 10 of 53 pa...